Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALA Calithera Biosciences	$0.03 -28.5%	$0.02	$0.01 ▼ $0.50	$122K	-0.17	857 shs	1,075 shs
CBIO Catalyst Biosciences		$0.77	$0.19 ▼ $8.69	$291.29M	1.05	763,526 shs	32,246 shs
KZIA Kazia Therapeutics	$0.38 +8.7%	$0.30	$0.19 ▼ $1.54	$6.14M	2.12	765,916 shs	296,186 shs
PLXP PLx Pharma		$0.00	$0.02 ▼ $0.04	$603K	3.79	12.96 million shs	3,000 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALA Calithera Biosciences	0.00%	+25.25%	0.00%	-19.84%	-51.83%
CBIO Catalyst Biosciences	0.00%	0.00%	0.00%	0.00%	+3,136.08%
KZIA Kazia Therapeutics	+8.61%	+5.62%	+34.77%	+7.43%	-75.10%
PLXP PLx Pharma	0.00%	0.00%	0.00%	0.00%	-99.29%

Urgent alert: open this for a huge profit potential (Ad)

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CBIO Catalyst Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	0.3138 of 5 stars	0.0	3.0	0.0	0.0	2.1	0.0	1.3
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALA Calithera Biosciences	N/A	N/A	N/A	N/A
CBIO Catalyst Biosciences	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALA Calithera Biosciences	$9.75M	0.01	N/A	N/A	($0.40) per share	-0.06
CBIO Catalyst Biosciences	$790K	0.00	N/A	N/A	($0.78) per share	0.00
KZIA Kazia Therapeutics	$20K	307.19	N/A	N/A	$0.50 per share	0.75
PLXP PLx Pharma	$4.54M	0.00	N/A	N/A	$1.30 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALA Calithera Biosciences	-$39.65M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CBIO Catalyst Biosciences	-$8.24M	-$1.38	N/A	N/A	N/A	N/A	-364.68%	-281.68%	N/A
KZIA Kazia Therapeutics	-$13.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	-$46.13M	-$1.85	N/A	N/A	N/A	-606.91%	-291.11%	-119.43%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A
CBIO Catalyst Biosciences	N/A	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALA Calithera Biosciences	N/A	N/A	N/A
CBIO Catalyst Biosciences	N/A	2.88	2.88
KZIA Kazia Therapeutics	N/A	0.71	N/A
PLXP PLx Pharma	N/A	4.79	4.28

Ownership

Institutional Ownership

Company	Institutional Ownership
CALA Calithera Biosciences	N/A
CBIO Catalyst Biosciences	5.98%
KZIA Kazia Therapeutics	30.89%
PLXP PLx Pharma	21.19%

Insider Ownership

Company	Insider Ownership
CALA Calithera Biosciences	6.60%
CBIO Catalyst Biosciences	2.92%
KZIA Kazia Therapeutics	1.00%
PLXP PLx Pharma	8.95%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CALA Calithera Biosciences	8	4.87 million	4.55 million	Not Optionable
CBIO Catalyst Biosciences	7	37.98 million	36.87 million	Optionable
KZIA Kazia Therapeutics	2,021	16.34 million	16.18 million	Optionable
PLXP PLx Pharma	16	29.14 million	26.53 million	Not Optionable

KZIA, PLXP, CALA, and CBIO Headlines

Source	Headline
	Protalix Biotherapeutics Inc (PLX) investing.com - January 30 at 9:00 AM
	Vertex Pharmaceuticals Inc VRTX morningstar.com - January 22 at 7:59 PM
	Vietnam National Petroleum Group (PLX) investing.com - October 23 at 10:13 AM
	PLx Pharma Inc (PLXPQ) uk.investing.com - August 21 at 4:54 AM
	Pharmaceutical R&D: the road to positive returns nature.com - July 16 at 9:22 AM
	PLXPQ PLx Pharma Inc. seekingalpha.com - April 21 at 11:49 PM
	PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE(R) and Substantially All of its Assets marketwatch.com - April 13 at 10:45 PM
	Why PLx Pharma Shares Are Nosediving Today msn.com - April 12 at 4:03 PM
	Why iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket msn.com - April 12 at 10:33 AM
	Why PLx Pharma Shares Are Down Over 40% Tuesday msn.com - April 11 at 11:47 PM
	PLx Pharma Inc. Receives Nasdaq Delisting Notice finance.yahoo.com - April 11 at 6:43 PM
	Short Volatility Alert: Plx Pharma Inc msn.com - April 11 at 1:42 PM
	PLx Pharma's Return On Capital Employed Insights msn.com - December 22 at 2:37 PM
	PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript seekingalpha.com - November 11 at 11:44 AM
	PLx Pharma down after Q3 revenue fell 94% Y/Y seekingalpha.com - November 11 at 11:44 AM
	PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update finance.yahoo.com - November 10 at 8:33 PM
	PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates finance.yahoo.com - November 10 at 8:33 PM
	Earnings Preview: PLx Pharma msn.com - November 10 at 3:32 PM
	PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update finance.yahoo.com - October 26 at 12:57 PM
	Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels finance.yahoo.com - September 12 at 9:15 PM
	PLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose another US$52k finance.yahoo.com - September 5 at 11:30 AM
	PLXP Aug 2022 5.000 call finance.yahoo.com - August 20 at 9:18 PM
	PLx Pharma downgraded at Oppenheimer after Q2 miss seekingalpha.com - August 15 at 2:42 PM
	PLx Pharma to Explore Strategic Alternatives, Reduces Team marketwatch.com - August 12 at 11:28 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Calithera Biosciences

NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Catalyst Biosciences

NASDAQ:CBIO

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

Kazia Therapeutics

NASDAQ:KZIA

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

PLx Pharma

NASDAQ:PLXP

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial